The rush of big pharma to buy oncology drugs as a growth element for their drug portfolios increasingly going off patent is no real news. Synta has a decent drug with Ganet., with some very interesting potential if Enchant and the complete responses were not statistical outliers. Add to this the new platform, and there is no reason why this company should not be a buyout candidate. Especially as the company is not attached to any thorny partnerships. Perhaps the company decided to internally auto fund via its wealthy insiders as a way to avoid partnerships which would dilute equity and scare off acquirers. The platform clinical trials will cost a lot of money, even if Ganet. is approved for lung cancer in the near term, Synta has zero marketing in place nor will it be able to pay for the marketing on its own. My bet is that if the patent filings for the new platform are legit, Synta may be gobbled up within the next six months.